Conditions

Tirzepatide's dual-action may significantly impact a person's weight management and blood glucose compared to GLP-1 receptor agonists like semaglutide.

Recent trials are showing that gastrointestinal surgery may be the new cure for type 2 diabetes, but few patients have access to it.

Study shows that breastfeeding can provide diabetes inhibiting effects for over three years.

In managing type 1 diabetes, a single combined formulation of pramlintide and prandial insulin can provide multiple benefits.

Insulin icodec is a novel once-weekly basal insulin analog for patients with type 2 diabetes.

Treating obstructive sleep apnea can decrease catecholamine, increase insulin sensitivity, and decrease pancreatic beta-cell apoptosis, leading to a lower risk of developing T2D.

What if there is an adjunct option in managing type 1 diabetes beyond insulin analogs in the form of GLP-1 RAs?

Tethered combination therapy for type 2 diabetes could be more beneficial than two medications taken concurrently.

CREDENCE trial shows that canagliflozin, an SGLT2 inhibitor, lowers the risk of cardiovascular and renal events in patients with T2DM, regardless of prior history of heart failure. 

Additional benefits are observed with dose escalation of semaglutide for patients with type 2 diabetes.